

## Prior Authorization

## JOHNS HOPKINS HEALTH PLANS (MEDICAID)

Sildenafil - Revatio Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at 1-410-424-4607. Please contact Johns Hopkins Health Plans at 1-888-819-1043 with questions regarding the Prior Authorization process.

When conditions are met, we will authorize the coverage of Sildenafil - Revatio Priority Partners MCO.

Drug Name (select from list of drugs shown)					
Revatio Oral Suspension (sildenafil)		Revatio Tablets	s (sildenafil)	Sildenafil	
Sildenafil Oral Suspension		Sildenafil Tablets			
Quantity	Frequency		Strength		
Route of Administration		Expected Length o	f Therapy		
Patient Information					
Patient Name:					
Patient ID:					
Patient Group No.:					
Patient DOB:					
Patient Phone:					
Dressribing Dhysisian					
Prescribing Physician					
Physician Name:					
Physician Phone:					
Physician Fax:					
Physician Address:					
City, State, Zip:					
Diagnosis:		ICD Code:			
Comments:					
Please circle the appropriate an	swer for each que	stion.			
1. Has the plan authorized	-		YN		
patient (i.e., previous a			T IN		
plan)?					
NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit.					
All pertinent criteria must be met in order to be eligible for benefit coverage.					
[If yes, skip to question 8.]					
2. Does the patient have a definitive diagnosis of pulmonary Y N arterial hypertension?					

	NOTE: Submission of medical records is required.
	[If no, no further questions.]
3.	Was the diagnosis of pulmonary arterial hypertension Y N confirmed by a cardiologist or pulmonologist by right heart catheterization?
	NOTE: Submission of medical records is required.
	[If no, no further questions.]
4.	Does the patient have World Health Organization (WHO) Y N Class II or Class III symptoms?
	NOTE: Submission of medical records is required.
	[If no, no further questions.]
5.	Has the pulmonary arterial hypertension progressed Y N despite surgical treatment and/or maximal medical treatment?
	NOTE: Submission of medical records is required.
	[If no, no further questions.]
6.	Has the patient had treatment failure with oral calcium Y N channel blockers?
	NOTE: Patients who have substantial reductions in pulmonary arterial pressure from short acting vasodilators at the time of catheterization may require high doses (e.g., nifedipine 240 milligrams per day (mg/day) or amlodipine 20 mg/day) \ NOTE: Submission of medical records is required.
-	[If yes, skip to question 9.]
7.	Is the patient unable to take oral calcium channel blockers, Y N or is their use inappropriate in this patient?
	NOTE: Submission of medical records is required.
	[If yes, skip to question 9.]
	[If no, no further questions.]
8.	Is there clinical documentation showing the patient has experienced improved exercise capacity or a delay in symptom worsening?
	NOTE: Submission of medical records is required.
	[If no, no further questions.]
9.	Is the patient receiving nitrate therapy? Y N
	[If yes, no further questions.]
10.	Is this a request for generic sildenafil? Y N
	[If yes, skip to question 13.]
11.	Has the patient previously failed an adequate trial of Y N generic sildenafil?
	NOTE: Submission of medical records is required.
	[If yes, skip to question 13.]
12.	Does the patient have an intolerance to generic sildenafil? Y N

NOTE: Submission of medical records is required.	
[If no, no further questions.]	
13. Will the requested drug be used in combination with one or Y N more drugs with the same pharmacology when the patient has not adequately responded to monotherapy?	
NOTE: Submission of medical records is required.	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date	

٦

Г